Considerations for the Use of Imaging Tools for Phase II Treatment Trials in Oncology

被引：44

作者：

Shankar, Lalitha K. ^{[1
]}

den Abbeele, AnnickVan ^{[2
]}

Yap, Jeff ^{[2
]}

Benjamin, Robert ^{[3
]}

Scheutze, Scott ^{[4
]}

FitzGerald, T. J. ^{[5
]}

机构：

[1] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Univ Michigan Hlth Syst, Ann Arbor, MI USA

[5] Qual Assurance Review Ctr, Providence, RI USA

来源：

CLINICAL CANCER RESEARCH | 2009年 / 15卷 / 06期

关键词：

POSITRON-EMISSION-TOMOGRAPHY; GASTROINTESTINAL STROMAL TUMORS; IMATINIB MESYLATE; FDG-PET; END-POINTS; THERAPY; CHEMOTHERAPY; EFFICACY; SAFETY; CT;

D O I：

10.1158/1078-0432.CCR-08-2030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the context of assessing tumor response, imaging tools have the potential to play a vital role in phase II and III treatment trials. If the imaging test is able to predict potential phase III success in a reliable fashion, it would be a useful tool in phase II trial design as it may provide for a more rapid and timely response assessment. The benefits and challenges of using anatomic imaging measures as well as the promising molecular imaging measures, primarily fluorodeoxyglucose-positron emission tomography, are discussed here. The general issues related to successful implementation of advanced imaging in the context of phase II treatment trials are discussed.

引用

页码：1891 / 1897

页数：7

共 31 条

[1] Novel Designs and End Points for Phase II Clinical Trials [J].

Adjei, Alex A. ;

Christian, Michaele ;

Ivy, Percy .

CLINICAL CANCER RESEARCH, 2009, 15 (06) :1866-1872

[2] We should desist using RECIST, at least in GIST [J].

Benjamin, Robert S. ;

Choi, Haesun ;

Macapinlac, Homer A. ;

Burgess, Michael A. ;

Patel, Shreyaskumar R. ;

Chen, Lei L. ;

Podoloff, Donald A. ;

Charnsangavej, Chuslip .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1760-1764

[3] CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings [J].

Choi, H ;

Charnsangavej, C ;

Faria, SD ;

Tamm, EP ;

Benjamin, RS ;

Johnson, MM ;

Macapinlac, HA ;

Podoloff, DA .

AMERICAN JOURNAL OF ROENTGENOLOGY, 2004, 183 (06) :1619-1628

[4] Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria [J].

Choi, Haesun ;

Charnsangavej, Chuslip ;

Faria, Silvana C. ;

Macapinlac, Homer A. ;

Burgess, Michael A. ;

Patel, Shreyaskumar R. ;

Chen, Lei L. ;

Podoloff, Donald A. ;

Benjamin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1753-1759

[5] Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas [J].

DeLaney, TF ;

Spiro, IJ ;

Suit, HD ;

Gebhardt, MC ;

Hornicek, FJ ;

Mankin, HJ ;

Rosenberg, AL ;

Rosenthal, DI ;

Miryousefi, F ;

Ancukiewicz, M ;

Harmon, DC .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (04) :1117-1127

[6] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].

Demetri, GD ;

von Mehren, M ;

Blanke, CD ;

Van den Abbeele, AD ;

Eisenberg, B ;

Roberts, PJ ;

Heinrich, MC ;

Tuveson, DA ;

Singer, S ;

Janicek, M ;

Fletcher, JA ;

Silverman, SG ;

Silberman, SL ;

Capdeville, R ;

Kiese, B ;

Peng, B ;

Dimitrijevic, S ;

Druker, BJ ;

Corless, C ;

Fletcher, CDM ;

Joensuu, H .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480

[7] Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors [J].

Desai, Jayesh ;

Shankar, Sridhar ;

Heinrich, Michael C. ;

Fletcher, Jonathan A. ;

Fletcher, Christopher D. ;

Manola, Judi ;

Morgan, JeffreyA. ;

Corless, Christopher L. ;

George, Suzanne ;

Tuncali, Kemal ;

Silverman, Stuart G. ;

Van den Abbeele, Annick D. ;

van Sonnenberg, Eric ;

Demetri, George D. .

CLINICAL CANCER RESEARCH, 2007, 13 (18) :5398-5405

[8] Alternate Endpoints for Screening Phase II Studies [J].

Dhani, Neesha ;

Tu, Dongsheng ;

Sargent, Daniel J. ;

Seymour, Lesley ;

Moore, Malcolm J. .

CLINICAL CANCER RESEARCH, 2009, 15 (06) :1873-1882

[9] Processes for quality improvements in radiation oncology clinical trials [J].

Fitzgerald, T. J. ;

Urie, Marcia ;

Ulin, Kenneth ;

Laurie, Fran ;

Yorty, Jeffrey ;

Hanusik, Richard ;

Kessel, Sandy ;

Jodoin, Maryann Bishop ;

Osagie, Gani ;

Cicchetti, M. Giulia ;

Pieters, Richard ;

McCarten, Kathleen ;

Rosen, Nancy .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 71 (01) :S76-S79

[10]

Gambhir SS, 2001, J NUCL MED, V42, p1S

← 1 2 3 4 →